Bay Area based Moonwalk Biosciences announced a $70M series B today to advance its adipose-targeted RNAi therapies for obesity and cardiometabolic diseases
Co-Founder and CEO Alex Aravanis discusses the need for improved treatments in the obesity space and why he thinks Moonwalk's RNAi platform is an ideal approach.
3 days ago
Cloverleaf Bio, a spinout out of Yale, announced $33M in seed financing today that will help it advance its work on a tRNA platform in oncology
Co-Founders Austin Draycott and Cole Lewis, describe the type of work they are doing (the co-lead programs target hepatocellular carcinoma and colorectal cancer) and the investors that participated in the financing, which include 4BIO Capital, AbbVie Ventures, Lilly, and Boehringer Ingelheim Venture Fund.
3 days ago
Pareto Securities Healthcare Conference: Sedana Medical's inhaled sedative drug/device combo is currently in front of FDA - they hope to change the ICU with it
CEO Johannes Doll describes what he believes are the advantages of an inhaled sedative vs the traditional IV. The company already has experience commercializing this in Europe, with 1 out of 7 ICU patients in Germany currently using it. The U.S. PDUFA date is April 16.
Sep 2
Pareto Securities Healthcare Conference: BioInvent believes that it has found the next big checkpoint in TNFR2 - this summer they had data both in solid and liquid tumors
CEO Martin Welschof walks us through recent ASCO (ovarian in combo with Keytruda) and EHA (CTLC) data for BI-1808, and describes why the company believes TNFR2 is a compelling checkpoint with wide applicability. Plus, BI-1206 (FcyRIIB), which will have NCSLC data later this year and BioInvent ultimately hopes to partner.
Sep 2
Pareto Securities Healthcare Conference: Orexo believes that nasal delivery is superior to other modalities for most uses - they plan to file their naloxone program with FDA immanently
CEO Nikolaj Sørensen walks us through all the potential benefits of delivering medicines via a nasal spray, would theoretically could even include the ability to cross the BBB for CNS conditions. Naloxone and epinephrine are the most advance, and Oroxo also has plans for a nasal spray GLP and vaccines.
Sep 2
Pareto Securities Healthcare Conference: Hansa Biopharma has a December 19 PDUFA date with FDA for its IgG depleting therapy that hopes to make more patients eligible for kidney transplant
CEO Renée Aguiar-Lucander describes the idea behind imlifidase and discusses the trial that led to the U.S. filing. Hansa has also recently confidentially filed for an IPO in the United States as well.
Sep 2
Pareto Securities Healthcare Conference: Mendus' cellular immunotherapy has been making progress in numerous cancers - being thoughtful about the setting and goal of treatment have been keys
CEO Erik Manting describes vididencel and the progress the company has been making in AML, CML, and ovarian cancer. Additional CML data is expected in this second half of the year.
Sep 2
A focus on cutting edge science and a busy year of presentations and partnerships has made Circio not just one of the fastest growing biotech companies in the Nordic region, but in all of Europe
Co-Founder & CEO Erik Wiklund highlights the potential of circular RNA and walks us through the work Circio is doing in gene and cell therapy, including heart and eye indications, CNS, and in vivo CAR-T. The company has raised approximately $65M USD this year, putting at the top of European biotech raises.
Sep 1
Sweden's BioArctic founded the science behind the Alzheimer's medicine Leqembi - 2026 has been busy with a Parkinson's program and a host of partnerships for its brain transporter technology advancing
CEO Gunilla Osswald talks about the recently approved self-administered subcu formulation of lecanemab, called IQLIK, and updates us on a Parkinson's program that is moving along. Plus, how BioArctic's transferrin based brain transporter technology is different than others, which has resulted in numerous prestigious pharma partnerships.
Sep 1
Remix Therapeutics announced earlier this summer plans to go public via a reverse merger - it's on the back of clinical data that was presented for its RNA modulator at ASCO
Co-Founder and CEO Pete Smith describes how Remix uses small molecules to stop the transcription of disease causing mRNAs. The lead program targets MYB and is in a phase 1/2 for adenoid cystic carcinoma. The reverse merger could close towards the end of year.
Aug 26
Epicrispr Biotechnologies closed a $90M series C on Tuesday to advance its epigenetic therapy toward pivotal studies in facioscapulohumeral muscular dystrophy (FSHD)
CEO Amber Salzman discusses the benefit of the raise, and contrasts the funding environment in biotech today versus previous years. Plus, she describes the unmet need in FSHD and how AI has already been helping the company understand the patient experience in its current clinical trial.
Aug 12
LifeMine Therapeutics announced a $263M raise today to help accelerate the development of its novel calcineurin activation inhibitor that aims to radically change the profile of organ transplants
Co-Founder, President & CEO Greg Verdine describes the toxicity issues associated with the immuosupressive drugs that transplant recipients currently receive, and explains how LIFE-001 is different. Plus, given how the therapy is designed to safely prevent T-cell activation and proliferation, there could also ultimately be an autoimmune use case as well.
Aug 6
From NYSE: Noetik has been building a large database from patient tumor samples to use AI to help understand which patients are more likely to respond to medicines in the future
CEO Ron Alfa describes the platform's design, and walks us through partnerships with Agenus and GSK.
Jul 23
From NYSE: Alloy Therapeutics, which has a service provider model of helping other companies develop therapies, recently crossed the $1B valuation mark on their series E and is now fully integrated
Founder & CEO Errik Anderson describes the company's capabilities today and highlights a recent detail to help Voro Therapeutics develop masked T-cell engagers as an example of Alloy's broad capabilities.
Jul 23
From NYSE: Anthropic called out Manifold Bio as a key feedback provider when they announced Claude for life sciences recently. CEO Gleb Kuznetsov explains, and updates us on the brain shuttle program
He describes why Manifold is focused on in vivo work, even to the extent that it is trying to develop a 'virtual organism'. Plus, an update on the brain shuttle program that is partnered with Roche (it is not a transferrin program), and he explains the Anthropic news.
Jul 23
From NYSE: Nabla Bio is using AI and its own dry and wet lab models to discover and develop new antibody and protein based therapeutics. One partner, Takeda, has already come back for more
Co-Founder and CEO Surge Biswas walks us through the platform and describes the type of work that Nabla is doing for partners. Currently, it already has struck deals with Bristol, Astra, and Takeda (twice).
Jul 23
Oxford, UK based Oxford BioTherapeutics has steadily been rolling out new partnerships, most recently with Bristol, Roche, and GSK, for its antibody and target discovery work
CEO Christian Rohlff describes the types of programs Oxford will be collaborating with these companies on, and discussed why the company has prioritized partnerships over an internal pipeline lately. Plus, details on a unique database the company has derived that could lead to even further programs and deals.
Jul 20
Oxford, UK based Sitryx has been busy lately with a deal announced with Boehringer Ingelheim, and its lead program targeting PKM2 in the clinic for atopic dermatitis
CEO Iain Kilty talks about Sitryx's approach to modulating inflammation and shares updates on the Boehringer deal, a program that has been received back from Lilly, and the company's clinical activities.
Jul 20
Oxford, UK based Brainomix has developed an AI based platform that is designed to help hospitals diagnose the existence and severity of strokes from scans quickly as every minute counts
CEO Michalis Papadakis describes the technology and how it has the potential to greatly increase the number of people who experience stroke, and more quickly. The platform is FDA-cleared and CE-marked in Europe, and in wide use in Europe today. The company is also working on a lung fibrosis diagnostic.
Jul 20
Novartis agreed to acquire London based Myricx Bio today for $1.1B up front and up to $400M in milestones. As Myricx's CEO tells us today at the company's HQ, this is all about novel ADC payloads
CEO Mohit Rawat discusses the deal and the scientific rationale for N-myristoyltransferase inhibitor (NMTi) payloads.
Jul 6
Abivax CEO Marc de Garidel discusses freshly released maintenance part 2 results for obefazimod in UC and describes how he believes it builds on initial data announced earlier this month
He discusses learnings from the company's previous data release in early June and how he believes the new data presented gives investors a fuller picture of the efficacy and safety profile of the therapy. He discusses next steps from a regulatory and business standpoint, clarifies a key point of investor confusion, and also provides an update on the company's Crohn's trial.
Jun 30
San Diego based Replicate Bioscience believes that self-replicating RNA (srRNA) has key advantages over linear or circular RNA. Last year Novo signed on as a partner in obesity and diabetes
Co-Founder and CEO Nathaniel Wang describes the biology, which is designed to be more durable, tolerable, and offer less frequent dosing. The lead internal program is a rabies vaccine, and there is early work on mono, RSV/hMPV/PIV, gout, and a cancer vaccine platform. Coverage brought to you by
Jun 26
Recludix will have initial clinical data for its SH2 STAT6 soon (2H 2026) - while it already made waves via a big partnership, a positive profile in humans could signal that SH2's time has arrived
CEO Nancy Whiting walks us through the biology of SH2 and the potential breadth of it as a therapeutics approach (there are 120 SH2 domains). The lead STAT6 program is in healthy volunters, and the company is also working on a BTK. Plus, her thoughts on HHS's new initiative to speed up clinical trials in the United States. Chapters Her thoughts on HHS's new trials initiative - 2:39 Recludix's work on SH2 - 6:51 Coverage brought to you by
Jun 26
While inhibiting the Hedgehog signaling pathway has typically been used in oncology, San Diego based Endeavor BioMedicines has one they believe is well suited for fibrotic diseases like IPF
John Hood, the successful biotech entrepreneur and Co-Founder and CEO of Endeavor, describes the biological hypothesis for Hedgehog inhibition in IPF and why he thinks ENV-101 is the right asset for it. It is currently in a phase 2b that will read towards the end of the year, and he believes the trial can show more than just a slowing of the disease. Coverage brought to you by
Jun 26
San Diego based Origami Therapeutics is developing next-generation protein degraders and correctors for CNS conditions - the lead program is focused on Huntington's disease
Founder & CEO Beth Hoffman describes how Origami's platform is different than other degrades like PROTACs, and how it specifically is designed to clear the mutant huntingtin protein. Plus, details on a global collaboration announced earlier this year with Ipsen. Coverage brought to you by
Jun 26
BIO 2026: Texas based Nanoscope Therapeutics is using optogenetics, or light to turn cells on or off, to try to restore vision for retinal conditions
CEO Sulagna Bhattacharya describes the science behind this, which is gene agnostic, and the work the company is going to develop it and seek approvals both in Japan and the United States.
Jun 26
Actio Biosciences has a precision medicine approach to rare diseases - promising preclinical data in a genetically defined epilepsy has them eagerly awaiting forthcoming clinical results
CEO David Goldstein, a geneticist, describes his frustration with patient care when medicines were lacking rare genetic diseases, and how it motivated him to embark on drug development. Actio's lead program targets KCNT-1 and is in the clinic - preclinical animal work showed that inhibiting the target worked well, and that it may be less of a developmental condition. Coverage brought to you by
Jun 25
Artiva's cell therapy approach to autoimmune conditions is unique because it is NK cell based, donor derived, and there is no engineering of the cells - they believe the benefit is already in the data
CEO Fred Aslan walks us through this unique program and its potential advantages, which include that it can be administered in the community setting and can also be redosed if necessary. A 350 patient randomized registration trial in rheumatoid arthritis will be underway this year. Coverage brought to you by
Jun 25
.png){kind=logo}